Understand what your gut health results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
Anaerostipes hadrus: A major butyrate producer in your colon
An anaerostipes hadrus test analyzes DNA from a small stool sample to quantify this specific gut bacterium and estimate its relative abundance in your microbiome. A. hadrus belongs to the Lachnospiraceae family and is known for producing butyrate, a short‑chain fatty acid that fuels colon cells. Modern sequencing methods—most commonly 16S rRNA gene profiling or whole‑genome (shotgun) metagenomics—read microbial genetic material to determine which organisms are present and in what proportions. Species‑level calls are most reliable with metagenomics; 16S often reports at the genus level. Results reflect your current ecosystem, not a fixed trait, and can vary with diet, medications, stress, illness, and timing.
Why this matters: A. hadrus contributes to SCFA pools, helps maintain a healthy mucus layer, and supports tight junctions that keep the gut barrier strong. These microbial functions touch digestion, immune tone, and metabolic signaling through pathways like the gut–brain and gut–liver axes. While microbiome science is evolving, consistent patterns—such as stable diversity and a robust set of butyrate producers—are linked with resilient gut function and calmer inflammation in observational studies, though more research is needed.
Why a butyrate specialist deserves its own marker
Think of A. hadrus as part of your gut’s “maintenance crew.” It ferments leftover carbohydrates and certain fibers into butyrate, which your colon cells use as a preferred fuel. Butyrate helps keep the gut lining tight, supports a balanced immune response in the intestinal wall, and participates in crosstalk that influences glucose and lipid handling. In practical terms, the level of A. hadrus can offer clues about why your digestion feels efficient on some days and touchy on others, or why your system reacts differently after antibiotics, travel, or a big diet shift. It also provides a readout on whether your microbiome currently favors SCFA production—one of the microbial signals tied to satiety hormones and post‑meal metabolism. If you’ve heard about GLP‑1 buzz around weight and glucose control, here’s a related idea: certain SCFAs nudge gut cells to release GLP‑1–like signals, though the effect sizes in humans vary and are still being quantified.
Testing is especially useful when you want to understand change over time: after a course of antibiotics, during recovery from a stomach bug, or when experimenting with dietary patterns that alter fermentable fiber (for example, moving from a low‑fiber, high‑protein plan to one with more legumes and resistant starch). It can also help contextualize persistent gastrointestinal symptoms—bloating, irregularity, or food sensitivity—by showing whether a core butyrate producer is underrepresented. Importantly, an anaerostipes hadrus test does not diagnose disease. Instead, it offers mechanistic insight you can combine with symptoms, diet history, and other biomarkers. From a prevention standpoint, keeping an eye on key SCFA producers is akin to watching engine temperature on a dashboard: you’re not fixing the engine with the gauge, but you are catching trends before problems escalate.
Reading your A. Hadrus number
Your report typically shows the relative abundance of A. hadrus compared with a reference population, sometimes alongside related functional pathways (e.g., butyrate synthesis genes). In general, balanced microbiomes include a cadre of butyrate producers; seeing A. hadrus within an expected range suggests your gut ecosystem supports SCFA generation and barrier maintenance. Because individual microbiomes vary by geography, diet, and age, “normal” spans a range rather than a single target value.
If results indicate a lower‑than‑expected abundance, it may point to reduced butyrate‑producing capacity at the time of sampling. That pattern often co‑occurs with lower overall diversity, recent antibiotic use, or limited fermentable fiber intake. If results are higher, it can reflect an ecosystem currently favorable to fiber fermentation and cross‑feeding among microbes. Very high relative abundance without diversity context can also occur when other groups are temporarily suppressed—another reason to interpret results in a broader panel.
What this means functionally: adequate SCFA support is linked to efficient nutrient processing, a calmer inflammatory tone in the colon, and a sturdier gut barrier. Conversely, an underrepresentation of butyrate producers may align with increased intestinal permeability signals or inflammation‑associated patterns on other tests, warranting clinical attention if symptoms persist.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Factors that nudge the number
Two practical caveats improve interpretation. First, methods matter: 16S assays may report at the genus level, which can blur species differences; shotgun metagenomics or targeted qPCR provide higher resolution. Second, stool captures what’s shed, not every niche of the gut, and results can shift day to day. For reliable trendlines, compare like with like—same collection timing, similar recent diet—and review your data alongside clinical context to personalize next steps.
Other data that adds context
Zooming out, your microbiome is a network. No single species tells the whole story, but A. hadrus sits at a helpful intersection of digestion, barrier integrity, and immune calm. Tracking it alongside diversity metrics and markers like fecal calprotectin (gut inflammation) or metabolic labs (glucose, triglycerides) provides a more complete map of how daily inputs translate into long‑term outcomes. The goal isn’t perfection—it’s pattern recognition that supports sustainable, evidence‑guided choices.
Frequently Asked Questions
References
- Allen-Vercoe E, Daigneault M, White A, Panaccione R, Duncan SH, Flint HJ, O'Neal L, Lawson PA (2012). Anaerostipes hadrus comb. nov., a dominant species within the human colonic microbiota; reclassification of Eubacterium hadrum Moore et al. 1976. *Anaerobe*, *18*(5), 523-529. https://doi.org/10.1016/j.anaerobe.2012.09.002
- Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell*, *165*(6), 1332-1345. https://doi.org/10.1016/j.cell.2016.05.041
- Durazzi F, Sala C, Castellani G, Manfreda G, Remondini D, De Cesare A (2021). Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota. *Scientific Reports*, *11*, 3030. https://doi.org/10.1038/s41598-021-82726-y
- Lynch SV, Pedersen O (2016). The human intestinal microbiome in health and disease. *The New England Journal of Medicine*, *375*(24), 2369-2379. https://doi.org/10.1056/NEJMra1600266
- Porcari S, Mullish BH, Asnicar F, Ng SC, Zhao L, Hansen R, O'Toole PW, Raes J, Hold G, Putignani L, Gasbarrini A, Segata N, Cammarota G (2025). International consensus statement on microbiome testing in clinical practice. *The Lancet Gastroenterology & Hepatology*, *10*(2), 154-167. https://doi.org/10.1016/S2468-1253(24)00311-X
